Evaluating a strategy of PAH therapy pre-treatment in patients with atrial septal defects and pulmonary arterial hypertension to permit safe repair (“treat-and-repair”)

Pulmonary arterial hypertension (PAH) associated with congenital heart disease (PAH-CHD) remains a major cause of morbidity and mortality in the growing adult congenital heart disease population. In the face of sustained progress, fewer patients are presenting with severe pulmonary vascular disease (PVD) and reversal of the shunt, cyanosis and multi-organ involvement, characteristic of Eisenmenger syndrome [ [1] Hjortshøj C.S. Jensen A.S....